Trial · NCT07251868
Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
NCT07251868, Recruiting, Peking University Cancer Hospital & Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study. Trials, record NCT07251868. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07251868
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
- NCT number
- NCT07251868
- Status
- Recruiting
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Conditions
- Breast Cancer, Brain Metastases From Breast Cancer, Trop2
- Interventions
- Sacituzumab Govitecan (SG)
- First posted
- 2025-11-26
- Last updated
- 2025-11-26
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Real world progression free survival (rwPFS) | up to 48 months from the initiation of the study treatment. | The time interval from the date of Sacituzumab Govitecan initiation until date of progressive disease (PD) or death from any causes, whichever occurred first. |
| Secondary | Real world objective response rate (rwORR) | approximately up to 24 weeks from the initiation of the study treatment. | The percentage of participants with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1. CR = Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. |
| Secondary | Real world overall survival (rwOS) | up to 48 months from the initiation of the study treatment. | Time from initiation of SG monotherapy or combination therapy to death from any cause |
| Secondary | Number of patients with adverse events | approximately up to 68 weeks from the initiation of the treatment. | Adverse events were assessed during study treatment and at follow-up visits |
| Secondary | CNS-PFS | Start of treatment until 2-year follow-up | Central nervous system- progression free survival: time from the date when the subject first received SG to the first observation of tumor progression of central nervous system or death from any cause. |
| Secondary | CNS-ORR | Start of treatment until 2-year follow-up | Central nervous system- objective response rate: proportion of subjects who achieved complete remission (CR) or partial remission (PR) of central nervous system by primary tumor imaging evaluation. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07251868
GET https://conductscience.org/api/trials/v1/NCT07251868/registered